No rivals for Suprax; Lupin eyes 22-25% domestic growth

In an interview with CNBC-TV18, Ramesh said he is not aware of any competition to the Suprax generic. He added, any other company filing for an approval of a similar generic version has to wait at least a couple of years to reach the market.

Further, Lupin is also looking forward to inorganic growth in Latin America and Russia. Ramesh is also hopeful of acquisitions ranging between USD 100 to 400 million.

Here is the edited transcript of the interview on CNBC-TV18.

Q: First your clarification on Suprax. Apparently a generic version is going to hit the market soon. Is that true, are you expecting some competition there?

A: I have actually not heard about it. In fact Suprax has been generic for quite some time, except that does not really have any competition. We do not know of anybody from India, from other parts of the world who have actually made a filing and even if somebody does that today, it will actually take a couple of years.

We believe that at least for the next couple of years, in the immediate line of sight, there will be no competition to Suprax.

Q: When do you expect to launch the Suprax drops?

A: We have not got approvals for that yet. So it could be possibly before the end of this fiscal.

Q: Can you update us on where things stand with the launch of generic Tricor?

A: We have actually settled with Abbot but, the terms of the settlement are actually confidential. We would not be in a position to talk about that. In any case we do not talk about impending launches. We could potentially be launching Tricor by the end of this fiscal.